Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kyverna Therapeutics Inc KYTX

Healthcare Biotechnology
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune... see more

Recent & Breaking News (NDAQ:KYTX)

Kyverna Therapeutics Inc And KYTX Stock Proprietors Are Welcomed To Engage In A Securities Fraud Examination Performed By The Schall Law Firm

Accesswire 18 hours ago

Kyverna Therapeutics Inc And KYTX Stock Possessors Are Requested To Be Part Of A Securities Fraud Inquiry Carried Out By The Schall Law Firm

Accesswire 1 day ago

Kyverna Therapeutics Inc And KYTX Stock Holders Are Invited To Join A Securities Fraud Probe Conducted By The Schall Law Firm

Accesswire 2 days ago

Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved In A Securities Fraud Probe Conducted By The Schall Law Firm

Accesswire 3 days ago

The Schall Law Firm Is Undertaking A Securities Fraud Probe Into Kyverna Therapeutics Inc And Encourages KYTX Shareholders To Join

Accesswire 4 days ago

Kyverna Therapeutics Inc And KYTX Stock Owners Are Encouraged To Participate In A Securities Fraud Investigation Led By The Schall Law Firm

Accesswire 5 days ago

The Schall Law Firm Is Conducting A Securities Fraud Investigation Into Kyverna Therapeutics Inc And Invites KYTX Shareholders To Participate

Accesswire 6 days ago

Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved In A Securities Fraud Probe Conducted By The Schall Law Firm

Accesswire 7 days ago

KYTX Shareholders Have The Opportunity To Participate In The Securities Fraud Investigation Of Kyverna Therapeutics Inc Led By The Schall Law Firm

Accesswire 8 days ago

The Schall Law Firm Is Conducting A Securities Fraud Probe Into Kyverna Therapeutics Inc And KYTX Shareholders Are Invited To Be Involved

Accesswire 9 days ago

KYTX Shareholders Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm

Accesswire 10 days ago

Shareholders Of KYTX Have The Opportunity To Participate In The Securities Fraud Scrutiny Of Kyverna Therapeutics Inc Led By The Schall Law Firm

Accesswire 11 days ago

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

PR Newswire 11 days ago

Investors Of KYTX Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc Conducted By The Schall Law Firm

Accesswire 12 days ago

KYTX Investors Can Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc By Schall Law Firm

Accesswire 13 days ago

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

PR Newswire June 17, 2024

Investors In KYTX Have The Chance To Participate In The Securities Fraud Probe Against Kyverna Therapeutics, Inc. With The Schall Law Firm

Accesswire June 17, 2024

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation

PR Newswire June 14, 2024

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Business Wire June 14, 2024

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

PR Newswire June 10, 2024